Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Go back to Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile| Harmony Metals, Inc. Common (NASDAQ: HRMY) | Delayed: 42.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.25 | 52 Week High | $1.35 | |||
| Open | $42.25 | 52 Week Low | $0.10 | |||
| Day High | $42.25 | P/E | N/A | |||
| Day Low | $42.25 | EPS | $0.00 | |||
| Volume | 40 | |||||
